The stock has a 36-month beta value of 2.47. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRBP is 10.38M, and at present, short sellers hold a 3.89% of that float. On April 10, 2024, the average trading volume of CRBP was 951.73K shares.
CRBP) stock’s latest price update
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has experienced a decline in its stock price by -6.70 compared to its previous closing price of 40.16. However, the company has seen a gain of 0.03% in its stock price over the last five trading days. 24/7 Wall Street reported 2024-03-17 that The Oracle of Omaha has once more bolstered his stake in a media giant’s tracking stocks.
CRBP’s Market Performance
Corbus Pharmaceuticals Holdings Inc (CRBP) has experienced a 0.03% rise in stock performance for the past week, with a -16.60% drop in the past month, and a 423.32% rise in the past quarter. The volatility ratio for the week is 9.07%, and the volatility levels for the past 30 days are at 10.32% for CRBP. The simple moving average for the last 20 days is -5.74% for CRBP’s stock, with a simple moving average of 191.83% for the last 200 days.
Analysts’ Opinion of CRBP
Many brokerage firms have already submitted their reports for CRBP stocks, with Jefferies repeating the rating for CRBP by listing it as a “Buy.” The predicted price for CRBP in the upcoming period, according to Jefferies is $46 based on the research report published on March 06, 2024 of the current year 2024.
ROTH Capital, on the other hand, stated in their research note that they expect to see CRBP reach a price target of $3, previously predicting the price at $40. The rating they have provided for CRBP stocks is “Neutral” according to the report published on September 08th, 2020.
CRBP Trading at 15.49% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.86% of loss for the given period.
Volatility was left at 10.32%, however, over the last 30 days, the volatility rate increased by 9.07%, as shares sank -2.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.06% upper at present.
During the last 5 trading sessions, CRBP rose by +0.03%, which changed the moving average for the period of 200-days by +377.32% in comparison to the 20-day moving average, which settled at $39.71. In addition, Corbus Pharmaceuticals Holdings Inc saw 520.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Cormorant Asset Management, LP, who purchase 300,000 shares at the price of $44.38 back on Mar 08 ’24. After this action, Cormorant Asset Management, LP now owns 2,025,000 shares of Corbus Pharmaceuticals Holdings Inc, valued at $13,314,193 using the latest closing price.
Cormorant Asset Management, LP, the 10% Owner of Corbus Pharmaceuticals Holdings Inc, purchase 250,000 shares at $40.05 during a trade that took place back on Mar 07 ’24, which means that Cormorant Asset Management, LP is holding 1,725,000 shares at $10,013,367 based on the most recent closing price.
Stock Fundamentals for CRBP
Current profitability levels for the company are sitting at:
- -33.4 for the present operating margin
- 0.39 for the gross margin
The net margin for Corbus Pharmaceuticals Holdings Inc stands at -33.74. The total capital return value is set at 12.45. Equity return is now at value -341.98, with -94.31 for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 1.49 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at -3.02. The interest coverage ratio of the stock is -2689.9.
Currently, EBITDA for the company is -44.44 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of 296.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To sum up, Corbus Pharmaceuticals Holdings Inc (CRBP) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
